Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 5, 2020

Primary Completion Date

November 24, 2021

Study Completion Date

November 24, 2021

Conditions
Familial Alzheimer Disease (FAD)PSEN1 Mutation
Interventions
DRUG

Bromocriptine Mesilate

Each tablet contains 2.87 mg of bromocriptine mesilate (JP) (2.5 mg of bromocriptine)

DRUG

Placebos

Identical tablets which contain no active ingredient

Trial Locations (8)

467-8602

Nagoya City University Hospital, Nagoya

606-8507

Kyoto University Hospital, Kyoto

514-8507

Mie University Hospital, Tsu

701-0192

Kawasaki Medical School Hospital, Kurashiki

590-0018

Asakayama Hospital, Sakai

565-0871

Osaka University, Suita

770-8503

Tokushima University Hospital, Tokushima

173-0015

Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo

All Listed Sponsors
collaborator

Mie University

OTHER

collaborator

Osaka University

OTHER

collaborator

Tokushima University

UNKNOWN

collaborator

Tokyo Metropolitan Institute for Geriatrics and Gerontology

UNKNOWN

collaborator

Asakayama Hospital

UNKNOWN

collaborator

Kawasaki Medical School Hospital

UNKNOWN

collaborator

Nagoya City University Hospital

UNKNOWN

collaborator

Time Therapeutics, Inc.

UNKNOWN

collaborator

Towa Pharmaceutical Co.,Ltd.

UNKNOWN

lead

Kyoto University

OTHER

NCT04413344 - Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease | Biotech Hunter | Biotech Hunter